Last update :
28/04/2024
References   References 2004  
Type : Journal
Web link : http://www.ajhp.org/cgi/content/abstract/62/13/1381

Research teams : King of Prussia - SmithKline Beecham Pharmaceuticals
Authors : Patel K, Hursting MJ.
Title : Compatibility of argatroban with abciximab, eptifibatide, or tirofiban during simulated Y-site administration.
Reference : Am J Health-Syst Pharm ; 62: 1381-1384. 2005

Level of Evidence : 
Physical stability : 
Chemical stability : 
Other methods : 
Comments : 

List of drugs
InjectionArgatroban Anticoagulant
Compatible 1 mg/ml + InjectionEptifibatide 2 mg/ml + NaCl 0,9% or Glucose 5%
Compatible 1 mg/ml + InjectionTirofiban 50 µg/ml + NaCl 0,9% or Glucose 5%
InjectionEptifibatide Anticoagulant
Compatible 2 mg/ml + InjectionArgatroban 1 mg/ml + NaCl 0,9% or Glucose 5%
InjectionTirofiban Anticoagulant
Compatible 50 µg/ml + InjectionArgatroban 1 mg/ml + NaCl 0,9% or Glucose 5%
Stability of mixtures
Not specified NaCl 0,9% or Glucose 5% 20°C-25°C Not specified
Injection Argatroban 0,5 mg/ml
Injection Eptifibatide 1 mg/ml
4 Hour
Not specified NaCl 0,9% or Glucose 5% 20°C-25°C Not specified
Injection Argatroban 0,9 mg/ml
Injection Eptifibatide 0,1 mg/ml
4 Hour
Not specified NaCl 0,9% or Glucose 5% 20°C-25°C Not specified
Injection Tirofiban 25 µg/ml
Injection Argatroban 0,5 mg/ml
4 Hour
Not specified NaCl 0,9% or Glucose 5% 20°C-25°C Not specified
Injection Tirofiban 5,5 µg/ml
Injection Argatroban 0,85 mg/ml
4 Hour

  Mentions Légales